Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
TrueBinding, Inc. is currently navigating 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. The portfolio is managed by 4 distinct examiners, which means each pending action is under the review of a unique official. This one-to-one ratio between actions and examiners ensures that the company's success is not tied to the decision-making of a single individual, but rather distributed across multiple reviewers. For the practitioner, this provides a variety of perspectives that can be beneficial for navigating complex technical rejections.
These filings are distributed among 3 distinct art units, showing a slight concentration of technical focus within the biotechnology sector. The busiest examiner, BELYAVSKYI, MICHAIL A, holds 1 pending office action, mirroring the balanced distribution seen across the entire portfolio. This structure requires the applicant to manage interactions with three different technical divisions, each with its own set of standards, while benefiting from the diverse perspectives of four different examiners. This arrangement suggests a focused yet technically diverse approach to biotechnological innovation.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (25%) |
| Double-patenting only | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BELYAVSKYI, MICHAIL A | 1 | 63.9% | +28.0% |
| HAMA, JOANNE | 1 | 25.4% | +40.2% |
| WANG, CHANG YU | 1 | 33.4% | +53.7% |
| ALLEN, MARIANNE P | 1 | 60.1% | +18.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18637068 | METHODS OF TREATING EYE DISEASE | BELYAVSKYI, MICHAIL A | — |
| 18492607 | ANTI-GAL3 ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF | HAMA, JOANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18053191 | METHODS OF TREATING OR INHIBITING CARDIOVASCULAR DISEASES | WANG, CHANG YU | 26d overdue |
| 18637068 | METHODS OF TREATING EYE DISEASE | BELYAVSKYI, MICHAIL A | — |
| 18492607 | ANTI-GAL3 ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF | HAMA, JOANNE | — |
| 17834703 | ANTI-GAL3 ANTIBODIES AND METHODS OF USE FOR INSULIN RESISTANCE | ALLEN, MARIANNE P | — |
| Art Unit | Apps |
|---|---|
| 1647 | 2 |
| 1644 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18637068 | METHODS OF TREATING EYE DISEASE | BELYAVSKYI, MICHAIL A | 1644 | §103§112Other | Non-Final OA | — | Pending | Apr 16, 2024 |
| 18492607 | ANTI-GAL3 ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF | HAMA, JOANNE | 1647 | §103§112Other | Non-Final OA | — | Pending | Oct 23, 2023 |
| 18053191 | METHODS OF TREATING OR INHIBITING CARDIOVASCULAR DISEASES | WANG, CHANG YU | 1675 | §112 | Final Rejection | 26d overdue | Pending | Nov 07, 2022 |
| 17834703 | ANTI-GAL3 ANTIBODIES AND METHODS OF USE FOR INSULIN RESISTANCE | ALLEN, MARIANNE P | 1647 | DP | Non-Final OA | — | Pending | Jun 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTrueBinding, Inc. has 4 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
Michail A Belyavskyi has the most, with 1 of TrueBinding, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
